Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionLegal & General Group Plc
Latest Disclosed Ownership934,881 shares
Latest Disclosed Value $ 309,324,079
Legal & General Group Plc reports 2.77% decrease in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 8, 2026 - Legal & General Group Plc filed a 13F-HR form disclosing ownership of 934,881 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $267,095,502 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 961,496 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of -2.77% during the quarter. The current value of the position is $243,536,500 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 934,881 -26,615 -2.77 309,324 -19.10 0.0715
2026-02-09 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 961,496 73,716 8.30 382,339 -5.56 0.0848
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 887,780 15,009 1.72 404,828 42.24 0.0908
2025-08-12 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 872,771 -8,340 -0.95 284,602 19.62 0.0706
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 881,111 52,194 6.30 237,918 21.98 0.0648
2025-02-13 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 828,917 37,188 4.70 195,052 -10.42 0.0516
2025-02-28 2024-09-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 791,729 29,810 3.91 217,749 17.61 0.0573
2024-11-14 2024-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 960,959 34,629 264,293 0.0551
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 960,959 34,629 264,293 0.0278
2025-05-29 2024-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 761,919 11,317 1.51 185,147 65.05 0.0523
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 926,330 5,135 225,098 0.0504
2025-05-29 2024-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 750,602 -7,902 -1.04 112,177 -22.74 0.0323
2024-07-01 2024-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 921,195 -9,744 137,672 0.0321
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 921,195 -9,744 137,672 0.0166
2025-05-29 2023-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 758,504 -36,167 -4.55 145,185 3.16 0.0451
2024-02-15 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 930,939 136,268 178,191 0.0457
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 794,671 -3,718 -0.47 140,736 -7.19 0.0491
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 798,389 67,367 9.22 151,646 3.56 0.0493
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 731,022 -1,333 -0.18 146,438 -15.86 0.0524
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 732,355 -22,137 -2.93 174,044 15.25 0.0668
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 754,492 -24,456 -3.14 151,019 32.93 0.0590
2022-08-22 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 778,948 21,526 2.84 113,610 -8.14 0.0402
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 757,422 77,852 11.46 123,680 7.32 0.0376
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 679,570 12,785 1.92 115,241 -8.46 0.0349
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 666,785 -16,625 -2.43 125,896 8.67 0.0409
2021-08-12 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 683,410 36,972 5.72 115,852 26.93 0.0387
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 646,438 1,066 0.17 91,271 8.81 0.0340
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 645,372 14,580 2.31 83,879 -8.67 0.0328
2020-11-13 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 630,792 -2,284 -0.36 91,843 -2.05 0.0410
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 633,076 29,439 4.88 93,765 42.66 0.0453
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 603,637 29,567 5.15 65,728 -0.59 0.0384
2020-02-13 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 574,070 40,774 7.65 66,116 54.16 0.0315
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 533,296 32,349 6.46 42,888 17.99 0.0899
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 500,947 26,365 5.56 36,349 -18.04 0.0196
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 474,582 107,682 29.35 44,349 65.78 0.0253
2019-02-15 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 366,900 26,958 7.93 26,751 -10.09 0.0207
2018-11-20 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 339,942 -569 -0.17 29,752 -11.29 0.0213
2018-08-10 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 340,511 -8,059 -2.31 33,537 -19.22 0.0259
2018-05-17 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 348,570 242,098 227.38 41,515 206.88 0.0317
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 106,472 74,112 229.02 13,528 255.81 0.0098
2017-11-09 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 32,360 4,477 16.06 3,802 70.95 0.0029
2017-08-03 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,883 3,144 12.71 2,224 75.39 0.0018
2017-05-12 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 24,739 -222,628 -90.00 1,268 -86.31 0.0011
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 247,367 -45,545 -15.55 9,261 -53.35 0.0086
2016-10-12 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 292,912 -4,030 -1.36 19,854 20.50 0.0201
2016-08-16 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 296,942 5,446 1.87 16,477 -9.95 0.0174
2016-05-16 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 291,496 2,229 0.77 18,297 -32.81 0.0203
2016-02-16 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 289,267 10,609 3.81 27,232 21.61 0.0308
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 278,658 252,952 984.02 22,393 626.81 0.0273
2015-07-31 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,706 23,389 1,009.45 3,081 1,173.14 0.0036
2015-05-14 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,317 2,317 242 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.